Cargando…
Proteomic Profiling of BRAFV600E Mutant Colon Cancer Cells Reveals the Involvement of Nucleophosmin/c-Myc Axis in Modulating the Response and Resistance to BRAF Inhibition by Vemurafenib
BRAFV600E mutations are found in approximately 10% of colorectal cancer patients and are associated with worse prognosis and poor outcomes with systemic therapies. The aim of this study was to identify novel druggable features of BRAFV600E-mutated colon cancer (CC) cells associated with the response...
Autores principales: | Grbčić, Petra, Fučkar Čupić, Dora, Gamberi, Tania, Kraljević Pavelić, Sandra, Sedić, Mirela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228139/ https://www.ncbi.nlm.nih.gov/pubmed/34201061 http://dx.doi.org/10.3390/ijms22126174 |
Ejemplares similares
-
The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein
por: Grbčić, Petra, et al.
Publicado: (2021) -
Secretome Screening of BRAFV600E-Mutated Colon Cancer Cells Resistant to Vemurafenib
por: Car, Iris, et al.
Publicado: (2023) -
Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro
por: Car, Iris, et al.
Publicado: (2023) -
Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent
por: del Bufalo, Francesca, et al.
Publicado: (2014) -
Novel Bis- and Mono-Pyrrolo[2,3-d]pyrimidine and Purine Derivatives: Synthesis, Computational Analysis and Antiproliferative Evaluation
por: Bistrović Popov, Andrea, et al.
Publicado: (2021)